Scientists from King's College London have succeeded in developing a promising treatment based on a drug called KCL-286, which was originally designed to treat spinal cord injuries and neuropathic pain.
The drug is distinguished by its ability to activate a vital pathway linked to vitamin A, allowing it to target the causes of Alzheimer's disease more broadly compared to current treatments.